Carson-Zagzebski Distinguished Lectureship On QIBA Profiles in Ultrasound
I Rosado-Mendez1*, P Carson2*, (1) University of Wisconsin-Madison, Madison, WI, (2) The University of Michigan Health System, Ann Arbor, MI
Presentations
(Saturday, 3/26/2022) 4:30 PM - 5:30 PM [Central Time (GMT-5)]
Room: Celestin ABC
The Quantitative Imaging Biomarker Alliance (QIBA) has gone beyond most standards' efforts, to attempt to characterize how an imaging measurement will perform clinically, in bias and variance, within and between different makes of imaging systems, if the various actors follow the profile. In ultrasound we have gone beyond the earliest profile efforts in CT and nuclear medicine to standardize techniques before, or in the early stages of commercial development of those measurements. None of the profile efforts are to the stage of predicting clinical performance, but the early-stage profiles are emerging with strong data from phantoms and, in some cases, modest studies in humans. The medical physicist is a key actor in this process.
This session will cover the ongoing efforts of the Pulse-Echo Quantitative Ultrasound (PEQUS) and Shear Wave Speed (SWS) biomarker committees of RSNA-QIBA to standardize the use PEQUS and SWS features as biomarkers of liver steatosis (fat infiltration) and fibrosis (development of fibrous connective tissue). Special emphasis will be paid to the role of the medical physicist in the implementation of standardized PEQUS and SWS protocols in their clinical practice. This discussion will include definition of roles and responsibilities, types of tests required to demonstrate compliance with the protocols, and initial experience from our group in implementing these tests.
This session will also cover two other QIBA biomarker committees: Volume Blood Flow (VBF) and Contrast Enhanced Ultrasound (CEUS). VBF estimates have been reported ubiquitously in ultrasound and other modalities, but the simplistic assumptions have made the results extremely unreliable. The QIBA VBF process integrates the true volumetric flow with high, <15% bias and variance and is being developed by three companies with reference software for comparison. CEUS, like much of ultrasound quantification, has been thought to be much less reliable than contrast studies in other modalities. The processing and even measurement scales differ strongly between brands. The QIBA CEUS biomarker effort has established procedures, processing and reporting for consistent, hopefully cross-brand results in phantoms. Measurements will be needed by some users to confirm that these results are available in the field.
Learning Objectives
1. Describe the Ultrasound QIBA biomarker committees’ initiatives.
2. Recognize the clinical importance of QIBA biomarker assessment.
3. Understand medical physicists’ role in ensuring QIBA biomarkers are assessed appropriately.
Handouts
- 174-60515-15991653-182338-1418885787.pdf (I Rosado-Mendez)
- 174-60516-15991653-182339-1324475833.pdf (P Carson)
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email